Travel pass: Pros may outweigh cons
IATA’s mobile application will allow travellers to store and manage certifications for Covid-19 tests or ...
Are vaccine-makers hesitant in undertaking bridging studies in India on vaccines developed overseas?
While some vaccine-makers keep their cards close to the chest, the scientific community is divided in its opinion on the need for such a trial, especially when the vaccine has received the regulatory go-ahead from a regulator like the United States Food and Drug Administration, for instance.
Presently, three foreign vaccines from AstraZeneca-Oxford University, Novavax and Gamaleya Institute’s Sputnik V have done or are undertaking local trials, through Serum Institute (for the first two) and Dr Reddy’s Laboratories, in the case of the last vaccine.
The other two vaccines of interest to India are from Pfizer, which applied for an emergency authorisation, but withdrew it, as additional data was sought. And more recently, Johnson and Johnson’s one-dose vaccine has just been approved in the US. J&J has a production alliance in India through Biological E, and a highly-placed source told BusinessLine that the company had sought no applications or waivers.
Regulatory officials and clinical researchers, on conditions of anonymity, say that bridging trials are required to understand how a vaccine works on the local population, as there are issues of ethnicity and so on. Besides, adds a researcher, the need for fast-track and seek a waiver makes sense early in the pandemic.
Presently, India appears to be comfortable with two vaccines being rolled out from Bharat Biotech and Serum Institute, and the Covid-19-linked mortality is less than the United States, for instance. So there is no compelling case to pedal back on the bridging study, he said. Besides, the expectation is that a third vaccine is close to getting approvals in the country (the reference being to Sputnik V).
Every country does what is good in its citizens' interest, he adds, pointing to the US taking its time on approving the AZ-Oxford vaccine. And this, even as Britain was the first off the block in authorising a vaccine from Pfizer.
Striking a contrarian note, vaccine expert Dr Vipin Vashishtha points out that a bridging trial was not required on a vaccine that has received regulatory approvals elsewhere. Such a study gives the immunogenicity levels or the level of antibodies created to protect a person, he points out. Some of the later vaccines have done global trials in a diverse population. In countries like South Africa that had variants of the virus, he says, indicating that authorities can go with the data from a vaccine tested against such challenges.
Another expert watching the developments adds that the regulatory requirement is not cast in stone, and the Government should take a nuanced approach. So while the country appears to be comfortable, he said, the vaccine maker may have a case for a waiver if the vaccine was seen to be effective against multiple variants. But broadly, bridging trials are required given local population and genetic variations, he added.
IATA’s mobile application will allow travellers to store and manage certifications for Covid-19 tests or ...
A 2010 Act to regulate the medical sector flounders in implementation, even as healthcare remains ...
The scheme to boost local medtech manufacturing is timely, especially given the raging pandemic. But ...
Do pilots sleep on their job?
Fiscal stimulus, friendly monetary policy and firm commodity prices point towards normalcy, says the MD and ...
Price correction is a good opportunity for long-term investors to take the plunge
Q4 earnings, along with progress in controlling Covid-19 spread, will be in focus
Do keep in mind that premium may go up in case one of the members has a pre-existing condition
In an age of falling female workforce participation, worsened by the Covid-19 pandemic, policy makers and ...
Of an injured baby goat, young men on motorcycles and political tensions
It’s the birthday of Muttiah Muralitharan — the man who took a staggering 800 test wickets. What better way to ...
An ode to writer and great-uncle Ved Mehta, and Ekarat, the friend who wrote and quit on his own terms
Monotype’s 2021 type trends report points to a return to hand and the familiar
As ‘ear-points’ between a company and a customer grow, we are witnessing a rise in audio assets
‘Desi Twitter challenger’ Koo on connecting like-minded folks
Coca-Cola has just introduced an oat milk line in the US under its Simply brand. Smart move, say industry ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor